Trial reportThorax1999
Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma.
Trial report in Thorax, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment.The Cochrane database of systematic reviews · 2000Pooled it
- Harnessing Exhaled Breath for Lung Cancer Early Detection-Results From the ExPeL Study.Clinical and translational science · 2026Article
- Single-cell RNA sequencing reveals transcriptional changes in circulating immune cells from patients with severe asthma induced by biologics.Experimental & molecular medicine · 2024Observational
- Epigenomic response to albuterol treatment in asthma-relevant airway epithelial cells.Clinical epigenetics · 2023Article
- NF-kappaB Signaling in Chronic Inflammatory Airway Disease.Biomolecules · 2015Review
- Inhaled corticosteroid influence toll like receptor 2 expression in induced sputum from patients with COPD.Translational respiratory medicine · 2013Article
- Ceramide-dependent PP2A regulation of TNFalpha-induced IL-8 production in respiratory epithelial cells.American journal of physiology. Lung cellular and molecular physiology · 2009Article
- Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease.Pharmacology & therapeutics · 2009Review
- Psychological factors in asthma.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2008Article
- Nuclear factor-kappaB: its role in health and disease.Journal of molecular medicine (Berlin, Germany) · 2004Review
- Pharmacotherapy and airway remodelling in asthma?Thorax · 2003Review
- Review
- Review
- Interactions between corticosteroids and beta2-agonists.Clinical reviews in allergy & immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInhaled corticosteroids and beta agonists are the most commonly used treatments in asthma and are often used together. Recent evidence suggests that many of the anti-inflammatory actions of corticosteroids are mediated by cross-talk between the activated glucocorticoid receptor (GR) and other transcription factors such as the pro-inflammatory nuclear factor kappa B (NFkappaB). Beta agonists can activate the transcription factor cAMP response element binding protein (CREB). A mutual inhibition between GR and CREB occurs in vitro which raises the possibility of a negative interaction between corticosteroid and beta agonist drugs. A study was undertaken to determine whether these interactions occur during treatment with beta2 agonists and corticosteroids in asthma.
methodsSeven subjects who were participating in a randomised, placebo controlled, crossover study of six weeks treatment with inhaled budesonide (400 microg twice daily), terbutaline (1 mg four times daily), and combined treatment were recruited. Biopsy samples of the bronchial mucosa were obtained after each treatment and analysed for the DNA binding activity of GR, CREB, and NFkappaB.
resultsBudesonide increased GR activity (p<0.05) and decreased NFkappaB activity (p<0.05). No treatment combination altered CREB activity and terbutaline had no significant effects on any transcription factor.
conclusionsInhaled corticosteroids have significant effects on GR and NFkappaB activity in bronchial mucosa. A negative interaction between inhaled corticosteroids and beta agonists was not found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.